Abstract
Optimizing management of patients with heart failure remains quite challenging despite many significant advances in drug and device therapy for this syndrome. Although a large body of evidence from robust clinical trials supports multiple therapies, utilization of these well-established treatments remains inconsistent and outcomes suboptimal in “real-world” patients with heart failure. Disease management programs may be effective, but are difficult to implement due to cost and logistical issues. Another approach to optimizing therapy is to utilize biomarkers to guide therapeutic choices. Natriuretic peptides provide additional information of significant clinical value in the diagnosis and estimation of risk inpatients with heart failure. Ongoing research suggests a potential important added role for natriuretic peptides in heart failure. Guiding therapy based on serial changes in these biomarkers may be an effective strategy to optimize treatment and achieve better outcomes in this syndrome. Initial, innovative, proof-of-concept studies have provided encouraging results and important insights into key aspects of this strategy, but well designed, large-scale, multicenter, randomized, outcome trials are needed to definitively establish this novel approach to management. Given the immense and growing public health burden of heart failure, identification of cost-effective ways to decrease the morbidity and mortality due to this syndrome is critical.
Keywords: Biomarker, guided, heart failure, natriuretic peptides.
Graphical Abstract
[1]
Adams K, Lindenfeld J, Arnold JMO, et al. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12: 10-38.
[2]
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013; (Jun): 5. [Epub ahead of print].
[3]
Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 2008; 168: 2481-8.
[4]
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: A report from the AmericanHeart Association. Circulation 2010; 121: e46-e215.
[5]
Lenzen MJ, Boersma E, Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on heart failure. Eur Heart J 2005; 26: 2706-13.
[6]
Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail 2007; 9: 292-9.
[7]
de Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007; 9: 1205-11.
[8]
Chan PS, Oetgen WJ, Buchanan D, et al. Cardiac performance measure compliance in outpatients: The American College of Cardiology and National Cardiovascular Data Registry’s PINNACLE (Practice Innovation and Clinical Excellence) program. J Am Coll Cardiol 2010; 56: 8-14.
[9]
Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. AmHeart J 2011; 1611024-30. : e1023.
[12]
Anderson ME, Mohler PJ. Rescuing a failing heart: Think globally, treat locally. Nat Med 2009; 15: 25-6.
[13]
Peters-Klimm F, Muller-Tasch T, Remppis A, Szecsenyi J, Schellberg D. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract 2008; 14: 823-9.
[14]
Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 2005; 45: 1654-64.
[15]
Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: Systematic review and meta-analysis. BMJ (Clinical research ed) 2007; 334: 942.
[16]
Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006; 113: 2335-62.
[17]
Tang WH, Francis GS, Morrow DA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116: e99-e109.
[19]
Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013; 127: 500-7. discussion 508.
[20]
Maisel A, Mueller C, Adams K Jr, Anker SD, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39.
[21]
Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007; 137: 4-12.
[22]
Adams KF Jr, Felker GM, Fraij G, Patterson JH, O’Connor CM. Biomarker guided therapy for heart failure: Focus on natriuretic peptides. Heart Fail Rev 2010; 15: 351-70.
[24]
Rehman SU, Januzzi JL Jr. Natriuretic peptide testing in clinical medicine. Cardiol Rev 2008; 16: 240-9.
[25]
Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. The Am J Cardiol 2008; 101: 3-8.
[26]
Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007; 12: 131-42.
[27]
Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41: 2280-7.
[28]
Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: A magnetic resonance imaging study. J Card Fail 2008; 14: 687-94.
[29]
Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47: 742-8.
[30]
Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
[31]
Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-54.
[32]
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
[33]
Babuin L, Jaffe AS. Troponin: The biomarker of choice for the detection of cardiac injury. CMAJ 2005; 173: 1191-202.
[34]
Peacock WFt, De Marco T, Fonarow GC, et al Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26.
[35]
Januzzi JL Jr. ST2 as a cardiovascular risk biomarker: From the bench to the bedside. J Cardiovasc Transl Res 2013. Apr 5 [Epub ahead of print].
[36]
de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7: 1-8.
[37]
de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 2012; 163: 821-8.
[38]
Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-25.
[39]
Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180-7.
[40]
Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-b-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60.
[41]
Pfisterer M, Buser P, Rickli H, et al. Bnp-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301: 383-92.
[42]
Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58: 1881-9.
[43]
Gaggin HK, Mohammed AA, Bhardwaj A, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 2012; 18: 626-34.
[44]
Karlstrom P, Alehagen U, Boman K, Dahlstrom U. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: Responders to treatment have a significantly better outcome. Eur J Heart Fail 2011; 13: 1096-103.
[45]
Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-9.
[46]
Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: Mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013; 15: 342-51.
[47]
Januzzi JL Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use. Arch Cardiovasc Dis 2012; 105: 40-50.
[48]
Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55: 645-53.
[49]
Sanders-van Wijk S, van Asselt ADI, Rickli H, et al. Cost-effectiveness of N-Terminal Pro-B-Type natriuretic-guided therapy in elderly heart failure patients: Results from TIME-CHF (Trial of Intensified versus Standard Medical therapy in Elderly patients with Congestive Heart Failure). J Am Coll Cardiol HF 2013; 1: 64-71.
[50]
Maeder MT, Rickenbacher P, Rickli H, et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus Standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2013. May 8 [Epub ahead of print].
[51]
Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. Am Heart J 2009; 158: 422-30.
[52]
Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med 2010; 170: 507-14.
[53]
Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92: 406-10.
[54]
Olsson LG, Swedberg K, Cleland JG, et al. Prognostic importance of plasma nt-pro bnp in chronic heart failure in patients treated with a beta-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007; 9: 795-801.
[55]
Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113: 977-85.
[56]
Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther 2008; 22: 305-11.
[57]
Latini R, Masson S, Anand I, et al. Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (VAL-Heft). Circulation 2002; 106: 2454-8.
[58]
Berry C, Murphy NF, De Vito G, et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 2007; 9: 429-34.
[59]
Smart NA, Meyer T, Butterfield JA, et al. Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. Eur J Prev Cardiol 2012; 19: 428-35.
[60]
Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007; 28: 1592-7.
Article Metrics
57
2
1
1